TENX Tenax Therapeutics Inc

Tenax Therapeutics to Discuss Third Quarter 2016 Financial Results and Provide Business Update

Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced that the Company will host a conference call and live audio webcast on Thursday, November 10, 2016, at 8:30 a.m. ET to discuss its third quarter 2016 financial results and provide a business update.

To participate in the call, please dial 866-932-0173 (domestic) or 785-424-1630 (international). A live webcast of the call can be accessed under “Events and Presentations” in the Investors section of the Company’s website at www.tenaxthera.com. An archived webcast recording will be available on the Tenax Therapeutics website beginning approximately two hours after the call.

About Tenax Therapeutics

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market. The Company owns the North American rights to develop and commercialize levosimendan, and the United States Food and Drug Administration (FDA) has granted Fast Track status for levosimendan for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome (LCOS). The Company is currently in a Phase 3 trial with levosimendan for that indication. For more information, visit www.tenaxthera.com.

EN
03/11/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tenax Therapeutics Inc

Tenax Therapeutics Inc: 1 director

A director at Tenax Therapeutics Inc bought 5,000 shares at 10.159USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch